ABBV
AbbVie Inc
AbbVie Inc historical holders
total: 16
Pzena Investment Management AbbVie Inc transactions over time
- Total transactions:
- 13
- New positions:
- 3
- Sold out:
- 3
- Added:
- 5
- Reduced:
- 2
- Held since:
- 2024 Q4
- Held for:
- 1 quarter
- Latest activity:
- 2025 Q1
Richard Pzena has been an institutional investor in AbbVie Inc (ABBV) since 2016 Q4. According to 2026 Q2 report, Richard Pzena doesn't hold any shares. The fund/company first acquired ABBV in 2016 Q4, initially purchasing 3,476 shares. Richard Pzena later completely sold out the position and reinvested in ABBV again in 2024 Q4. Since the initial investment, Pzena Investment Management has made 12 more transactions in this position.
When did Richard Pzena exit their ABBV position?
Richard Pzena no longer holds AbbVie Inc (ABBV). They sold off their entire position in 2025 Q1, closing out an investment that began in 2016 Q4.
When did Richard Pzena first invest in ABBV?
Richard Pzena first invested in AbbVie Inc (ABBV) in 2016 Q4 at the reported quarter-end price of $62.72 per share, acquiring 3,476 shares in their initial purchase.
What is Richard Pzena's average cost basis for ABBV?
Based on historical transaction data, Richard Pzena's estimated cost basis for AbbVie Inc (ABBV) is approximately $177.70 per share. This represents their average reported price* across all buy transactions.
Has Richard Pzena reinvested in ABBV after selling?
Yes, Richard Pzena has shown renewed interest in AbbVie Inc (ABBV). After completely selling their position, they reinitiated an investment in 2024 Q4, demonstrating continued conviction in this ticker.
Estimated cost basis*
- Weighted AVG buy price:
- $177.70
- Weighted AVG sell price:
- $177.70
ABBV transactions history by Pzena Investment Management
13 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q1
|
0.00%
|
0
|
$177.70
|
|
-100% (-1,670)
|
-0%
|
|
2024 Q4
|
0.00%
|
1,670
|
$177.70
|
$296,759
|
new
|
+0%
|
|
2021 Q2
|
0.00%
|
0
|
$108.29
|
|
-100% (-6,344)
|
-0%
|
|
2021 Q1
|
0.00%
|
6,344
|
$108.29
|
$687,000
|
+1.78% (+111)
|
+0%
|
|
2020 Q4
|
0.00%
|
$107.17
|
+2.26% (+138)
|
|||
|
2020 Q3
|
0.00%
|
$87.61
|
-15.64% (-1,130)
|
|||
|
2020 Q2
|
0.00%
|
$98.13
|
-10.24% (-824)
|
|||
|
2020 Q1
|
0.00%
|
$76.16
|
+153.19% (+4,870)
|
|||
|
2019 Q3
|
0.00%
|
$75.81
|
new
|
|||
|
2017 Q3
|
0.00%
|
$72.42
|
-100% (-5,137)
|
|||
|
2017 Q2
|
0.00%
|
$72.42
|
+23.19% (+967)
|
|||
|
2017 Q1
|
0.00%
|
$65.23
|
+19.97% (+694)
|
|||
|
2016 Q4
|
0.00%
|
$62.72
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.